GenNext Technologies, Inc., a growth-stage company providing biopharmaceutical drug discovery systems and services, announced today the receipt of a two year, Phase II SBIR grant for a project titled “In-Cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System.”
GenNext Technologies highlights the grant was awarded by the National Institute of General Medical Systems (NIGMS) of the U.S. Department of Health and Human Services. The purpose of the grant is to extend GenNext’s breakthrough Hydroxyl Radical Protein Footprinting (HRPF) technology and methods to studies involving living cells.
This award of $2.5 million brings total funding from NIGMS for the GenNext platform to $9.5 million.
The Flash Oxidation (Fox™) Protein Footprinting System is currently being used by the biopharmaceutical industry to perform Higher Order Structure (HOS) analysis of proteins with an emphasis on biologic therapeutics, the most rapidly growing segment in this area. The Fox System helps researchers develop safer and more effective biotherapeutics by revealing important information about protein interactions and structural changes.
“With this award, we will complete our in-cell protein footprinting R&D program, culminating in a revolutionary new tool to study protein structure, protein interactions, and drug interactions in living cells. Soon, researchers will study living cells with a new level of simplicity and elegance, while generating unprecedented levels of actionable data,” said Scot R. Weinberger, Founder and CEO of GenNext. “We’re truly delighted to receive our tenth NIGMS grant award as further validation of our leadership in commercializing novel and robust protein footprinting technology.”